Novo Signs $1.3 Billion Nanexa Deal for Long-Acting Drugs
Deals·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB. This agreement is part of Novo's strategy to grow amid a looming patent cliff.
Novo NordiskNanexa
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB, the latest in a string of small acquisitions as the Danish company tries to ensure it can grow”
Bloomberg — Novo Signs $1.3 Billion Nanexa Deal for Long-Acting Drugs